Quick Answer
BridgeBio Pharma, Inc. reported Stockholders Equity of -$2.09 billion for fiscal year 2025.
BridgeBio Pharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$2.09B | -42.1% |
| 2024 | -$1.47B | -8.4% |
| 2023 | -$1.35B | -7.9% |
| 2022 | -$1.25B | -44.1% |
| 2021 | -$870.41M | -1603.1% |
| 2020 | $57.91M | -85.8% |
| 2019 | $408.45M | +29.7% |
| 2018 | $314.88M | +266.8% |
| 2017 | $85.85M | +476.6% |
| 2016 | $14.89M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.93B | -57.2% | -8.1% |
| June 30, 2025 | -$1.79B | -63.6% | -8.5% |
| March 31, 2025 | -$1.65B | -57.1% | -12.3% |
| December 31, 2024 | -$1.47B | -8.4% | -19.3% |
| September 30, 2024 | -$1.23B | -1.9% | -12.5% |
| June 30, 2024 | -$1.09B | +19.8% | -4.1% |
| March 31, 2024 | -$1.05B | +14.4% | +22.5% |
| December 31, 2023 | -$1.35B | -7.9% | -12.1% |
- BridgeBio Pharma, Inc. showed a decrease of -42.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, BridgeBio Pharma, Inc.’s stockholders equity has declined by 14114.4% (from $14.89 million to -$2.09 billion).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: